This article is more than 5 years old. Information may no longer be current.
Molecular test predicts survival in prostate cancer
Click Here to Manage Email Alerts
A new molecular diagnostic tool, Prolaris, accurately predicted survival in patients with prostate cancer, according to data.
The 46-gene panel examines standard prostate tumor tissue to assess whether a patient has a slow-growing form of prostate cancer or a more aggressive form.
Researchers pooled data on 337 patients with clinically localized prostate cancer diagnosed between 1990 and 1996.
The panel accurately predicted morbidity associated with prostate cancer when compared with traditional clinical and laboratory measurements. Results indicated that 25% of patients had a favorable score with a 98.5% chance of disease survival over 10 years.
Conversely, patients assigned an unfavorable score had a 42.4% chance of disease survival over 10 years. Researchers noted that 25% of patients in the study had this result, indicating an aggressive prostate cancer that should be treated more intensively.
“This exciting study further demonstrates the potential for Prolaris to transform the care of prostate cancer in patients by leveraging the test’s ability to outperform traditional and clinical risk factors in the prediction of prostate cancer,” Jerry Lanchbury, PhD, chief scientific officer at Myriad Genetics, said in a press release.
For more information:
- Lanchbury J. #158O. Presented at: the ESMO 35th Congress; Oct. 8-12, 2010; Milan, Italy.